$0.73
+0.03
(+3.88%)▲
9.59%
Downside
Day's Volatility :9.59%
Upside
0.0%
28.68%
Downside
52 Weeks Volatility :92.75%
Upside
89.83%
Period | Briacell Therapeutics Corp | Index (Russel 2000) |
---|---|---|
3 Months | -47.55% | 0.0% |
6 Months | -74.86% | 0.0% |
1 Year | -89.1% | 0.0% |
3 Years | -89.14% | -22.3% |
Market Capitalization | 13.3M |
Book Value | - $0.37 |
Earnings Per Share (EPS) | -0.37 |
Wall Street Target Price | 18.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -122.71% |
Return On Equity TTM | -206.01% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -35.3M |
Diluted Eps TTM | -0.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.39 |
EPS Estimate Next Year | -1.0 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 2365.75%
Sell
Neutral
Buy
Briacell Therapeutics Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Briacell Therapeutics Corp | 21.5% | -74.86% | -89.1% | -89.14% | -81.31% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Briacell Therapeutics Corp | NA | NA | NA | -1.39 | -2.06 | -1.23 | NA | -0.37 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Briacell Therapeutics Corp | Buy | $13.3M | -81.31% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Briacell Therapeutics Corp
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 126.2%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 158.3%
Lynwood Capital Management Inc.
BMO Capital Markets Corp.
Bank of Montreal
Redmond Asset Management, LLC
Onyx Bridge Wealth Group LLC
Summit Trail Advisors, LLC
briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.
Organization | Briacell Therapeutics Corp |
Employees | 16 |
CEO | Dr. William V. Williams M.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.73
+3.88%
Keyarch Acquisition Corp
$0.73
+3.88%
Connexa Sports Technologies Inc
$0.73
+3.88%
Us Value Etf
$0.73
+3.88%
First Wave Biopharma Inc
$0.73
+3.88%
Global X Msci Next Emerging
$0.73
+3.88%
Fat Projects Acquisition Corp
$0.73
+3.88%
Capital Link Global Fintech
$0.73
+3.88%
Applied Uv Inc
$0.73
+3.88%